Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Respir Med Res ; 81: 100913, 2022 May.
Artículo en Inglés | MEDLINE | ID: covidwho-2114708

RESUMEN

BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the main limitation to long-term survival following lung transplantation. Several studies generated promising results regarding the efficacy of extracorporeal photopheresis (ECP) in BOS management. We aimed to compare FEV1 evolution in ECP-treated versus non-ECP treated patients among BOS recipients. METHODS: Overall, 25 BOS patients were included after receiving optimized treatment. Data were collected retrospectively. Twelve patients with moderate and refractory BOS received ECP treatment. RESULTS: Among non-ECP treated control patients (n = 13), six experienced persistent decline without undergoing ECP for various reasons. ECP stabilized pre-ECP lung function during the subsequent 6 to 24 months (repeated measures one-way Anova, p = 0.002), without any significant impact observed by either FEV1 decline speed prior to ECP or time between BOS diagnosis and ECP onset. ECP-treated patients displayed a similar risk of an additional permanent 20% or higher drop in FEV1 after BOS onset compared to controls, but a lower risk compared to control decliners (p = 0.05). ECP quickly stabilized FEV1 decline in refractory BOS patients compared to non-treated decliners. CONCLUSIONS: We confirmed that this therapeutic option against refractory BOS can be managed in a medium-size LTx center, with a satisfactory efficacy and an acceptable tolerance.


Asunto(s)
Bronquiolitis Obliterante , Trasplante de Pulmón , Fotoféresis , Bronquiolitis Obliterante/etiología , Bronquiolitis Obliterante/terapia , Humanos , Trasplante de Pulmón/efectos adversos , Fotoféresis/efectos adversos , Fotoféresis/métodos , Estudios Retrospectivos , Síndrome
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA